260 related articles for article (PubMed ID: 19749094)
1. The role of B cells in the pathogenesis of graft-versus-host disease.
Shimabukuro-Vornhagen A; Hallek MJ; Storb RF; von Bergwelt-Baildon MS
Blood; 2009 Dec; 114(24):4919-27. PubMed ID: 19749094
[TBL] [Abstract][Full Text] [Related]
2. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.
Alousi AM; Uberti J; Ratanatharathorn V
Leuk Lymphoma; 2010 Mar; 51(3):376-89. PubMed ID: 20141428
[TBL] [Abstract][Full Text] [Related]
3. B cells in chronic graft-versus-host disease.
McManigle W; Youssef A; Sarantopoulos S
Hum Immunol; 2019 Jun; 80(6):393-399. PubMed ID: 30849450
[TBL] [Abstract][Full Text] [Related]
4. B-cell involvement in chronic graft-versus-host disease.
Kapur R; Ebeling S; Hagenbeek A
Haematologica; 2008 Nov; 93(11):1702-11. PubMed ID: 18728020
[TBL] [Abstract][Full Text] [Related]
5. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
6. Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease.
Rozmus J
Front Immunol; 2020; 11():574569. PubMed ID: 33613511
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
10. B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy.
Kim SJ; Won JH
Leuk Lymphoma; 2012 Jan; 53(1):19-25. PubMed ID: 21740304
[TBL] [Abstract][Full Text] [Related]
11. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
12. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
Kumar S; Leigh ND; Cao X
Front Immunol; 2018; 9():3003. PubMed ID: 30627129
[TBL] [Abstract][Full Text] [Related]
13. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
Kharfan-Dabaja MA; Bazarbachi A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
[TBL] [Abstract][Full Text] [Related]
15. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
16. Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation.
Skert C; Perucca S; Chiarini M; Giustini V; Sottini A; Ghidini C; Martellos S; Cattina F; Rambaldi B; Cancelli V; Malagola M; Turra A; Polverelli N; Bernardi S; Imberti L; Russo D
PLoS One; 2017; 12(4):e0175337. PubMed ID: 28399164
[TBL] [Abstract][Full Text] [Related]
17. Advances in understanding the pathogenesis of graft-versus-host disease.
Magenau J; Runaas L; Reddy P
Br J Haematol; 2016 Apr; 173(2):190-205. PubMed ID: 27019012
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.
Dander E; Balduzzi A; Zappa G; Lucchini G; Perseghin P; Andrè V; Todisco E; Rahal D; Migliavacca M; Longoni D; Solinas G; Villa A; Berti E; Mina PD; Parma M; Allavena P; Biagi E; Rovelli A; Biondi A; D'Amico G
Transplantation; 2009 Dec; 88(11):1261-72. PubMed ID: 19996925
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic.
Gu G; Yang JZ; Zhang JQ; Sun LX
Cell Immunol; 2019 Dec; 346():103991. PubMed ID: 31607390
[TBL] [Abstract][Full Text] [Related]
20. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]